Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being…
Clinically Proven Human Milk Probiotic LC40 supports Infant Health and Breastfeeding Mothers
SINGAPORE, Sept. 15, 2025 /PRNewswire/ --Â Supported by six clinical studies and two…
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
September 11, 2025 09:00 ET Â | Source: Nacuity Pharmaceuticals, Inc. NPI-001 shows…
Imaging Endpoints Announces Patent Application for AI Review Charter System
SCOTTSDALE, Ariz., Sept. 10, 2025 /PRNewswire/ -- Imaging Endpoints (IE), the global…
KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025
RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist…
Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025
September 09, 2025 11:00 ET Â | Source: Chiesi Global Rare Diseases Results…
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Medidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience Forward
Medidata eCOA was the highest Leader recognized in the evaluation, supporting over…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
September 04, 2025 20:00 ET Â | Source: HUTCHMED (China) Limited HONG KONG…
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,…